Skip to main content
Clinical Trials/IRCT201701172709N43
IRCT201701172709N43
Completed
Phase 2

The effect of oral quercetin supplement intake on oxidative markers , serum iron, liver enzymes and inflammatory indices in ß-thalassemia major patients,a double-blind placebo-controlled clinical trial

Vice chancellor for research, Iran University of Medical Sciences0 sites84 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
beta thalassemia major.
Sponsor
Vice chancellor for research, Iran University of Medical Sciences
Enrollment
84
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice chancellor for research, Iran University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • 18 to 30 year old male and female beta thalassemia major patients; Inclination to cooperate and signing the written informed consent; A minimum of 2 years of blood transfusion history; blood specimen collection 20 days after the last blood transfusion; Regular and peculiar iron\-chelating therapy with desferrioxamine; Vitamin C supplement intake with desferrioxamine; Serum ferritin level between 2500 to 3500 ng/ml
  • Exclusion criteria:
  • Uncontrollable and life threatening complication due to due to the supplement intake; A change in type or amount of the iron chelator; Pregnancy or lactation; Splenectomy; Hepatitis infection and other metabolic or infectious diseases; Less than 80% compliance of supplement intake; Consumption of drugs that interfere with quercetin; Drinking more than 500 mg/day of beverages rich in flavonoids; Smoking or alcohol consumption

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials